Sinopharm Group Co. Ltd (X2S) - Total Liabilities

Latest as of December 2025: €256.20 Billion EUR ≈ $299.53 Billion USD

Based on the latest financial reports, Sinopharm Group Co. Ltd (X2S) has total liabilities worth €256.20 Billion EUR (≈ $299.53 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Sinopharm Group Co. Ltd (X2S) equity growth momentum to track the company's year-over-year net asset growth rate.

Sinopharm Group Co. Ltd - Total Liabilities Trend (2013–2025)

This chart illustrates how Sinopharm Group Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. See X2S free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Sinopharm Group Co. Ltd Competitors by Total Liabilities

The table below lists competitors of Sinopharm Group Co. Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Veeco Instruments Inc NASDAQ:VECO	USA	$469.31 Million
FangDa Carbon New Material Co Ltd SHG:600516	China	CN¥3.17 Billion
Tofas Turk Otomobil Fabrikasi AS IS:TOASO	Turkey	TL141.85 Billion
Green Brick Partners Inc NYSE:GRBK	USA	$542.50 Million
Topco Scientific Co Ltd TW:5434	Taiwan	NT$24.34 Billion
Chipbond Technology TWO:6147	Taiwan	NT$6.86 Billion
Caida Securities Co Ltd SHG:600906	China	CN¥48.54 Billion
Vidrala SA MC:VID	Spain	€901.35 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Sinopharm Group Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Sinopharm Group Co. Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.41	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.05	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.66	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sinopharm Group Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sinopharm Group Co. Ltd (2013–2025)

The table below shows the annual total liabilities of Sinopharm Group Co. Ltd from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	€256.20 Billion ≈ $299.53 Billion	-3.74%
2024-12-31	€266.14 Billion ≈ $311.15 Billion	+1.17%
2023-12-31	€263.08 Billion ≈ $307.56 Billion	+3.29%
2022-12-31	€254.71 Billion ≈ $297.78 Billion	+8.04%
2021-12-31	€235.76 Billion ≈ $275.63 Billion	+6.54%
2020-12-31	€221.29 Billion ≈ $258.71 Billion	+14.69%
2019-12-31	€192.95 Billion ≈ $225.58 Billion	+15.20%
2018-12-31	€167.50 Billion ≈ $195.82 Billion	+41.62%
2017-12-31	€118.27 Billion ≈ $138.27 Billion	+4.50%
2016-12-31	€113.18 Billion ≈ $132.32 Billion	+14.84%
2015-12-31	€98.55 Billion ≈ $115.22 Billion	+6.70%
2014-12-31	€92.37 Billion ≈ $107.99 Billion	+20.20%
2013-12-31	€76.84 Billion ≈ $89.84 Billion	--

About Sinopharm Group Co. Ltd

F:X2S Germany Medical Distribution

Market Cap

$3.05 Billion

€2.61 Billion EUR

Market Cap Rank

#4783 Global

#810 in Germany

Share Price

€1.95

Change (1 day)

+0.10%

52-Week Range

€1.77 - €2.37

All Time High

€2.71